



ESC SPRING SUMMIT 2024

Prevention regains the forefront of the CVD agenda

What do the ESC Prevention guidelines say?

Konstantinos Koskinas, MD

07. March 2024



ESC

European Society
of Cardiology

European Heart Journal (2021) 42, 3227–3337
doi:10.1093/eurheartj/ehab484

ESC GUIDELINES



2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies

With the special contribution of the European Association of Preventive Cardiology (EAPC)


Authors/Task Force Members: Frank L.J. Visseren* (Chairperson) (Netherlands), François Mach* (Chairperson) (Switzerland), Yvo M. Smulders[†] (Task Force Coordinator) (Netherlands), David Carballo[†] (Task Force Coordinator) (Switzerland), Konstantinos C. Koskinas (Switzerland), Maria Bäck (Sweden), Athanasios Benetos⁸ (France), Alessandro Biffi^{7,10} (Italy), José-Manuel Boavida⁹ (Portugal), Davide Capodanno (Italy), Bernard Cosyns (Belgium), Carolyn Crawford (Northern Ireland), Constantinos H. Davos (Greece), Ileana Desormais (France), Emanuele Di Angelantonio (United Kingdom), Oscar H. Franco (Switzerland), Sigrun Halvorsen (Norway), F. D. Richard Hobbs¹³ (United Kingdom), Monika Hollander (Netherlands), Ewa A. Jankowska (Poland), Matthias Michal¹¹ (Germany), Simona Sacco⁶ (Italy), Naveed Sattar (United Kingdom), Lale Tokgozoglu² (Turkey), Serena Tonstad (Norway), Konstantinos P. Tsioufis⁵ (Greece), Ineke van Dis³ (Netherlands), Isabelle C. van Gelder (Netherlands), Christoph Wanner⁴ (Germany), Bryan Williams (United Kingdom), ESC Scientific Document Group


What is new in the 2021 CVD Prevention Guidelines?

- Stepwise approach to individualized CVD prevention
- SCORE2 and SCORE2-OP for 4 geographic regions
- Age-specific risk thresholds in apparently healthy persons
- Estimation of lifetime CVD risk and treatment benefit
- Shared decision making by taking patient specific conditions, patient preferences, (lifetime) risk and treatment benefit into account
- Signalling potential cost issues

Prevention of CVD

Visseren FLJ, et al. Eur Heart J. 2021;42:3227-337






**Risk regions based on
World Health Organization
CV mortality rates**

Visseren FLJ, et al. Eur Heart J. 2021;42:3227-337

SCORE2 & SCORE2-OP

10-year risk of (fatal and non-fatal) CV events in populations at low CVD risk



Women



Men

Non-smoking

Smoking

Non-smoking

Smoking

Non-HDL cholesterol

Systolic blood pressure (mmHg)
SCORE2-OP

3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
150 200 250

3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
150 200 250

mmol/L
mg/dL
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
150 200 250

3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
150 200 250

3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
150 200 250

160-179

28 29 30 31

31 32 33 34

29 35 42 49

29 35 42 49

29 35 42 49

140-159

26 27 28 29

29 30 31 32

28 33 40 47

27 33 40 47

27 33 40 47

120-139

24 25 26 27

27 28 29 30

26 32 38 45

26 32 38 45

26 32 38 45

100-119

23 24 25 26

25 26 27 28

25 30 36 43

25 30 36 43

25 30 36 43

160-179

20 21 22 23

25 26 28 29

23 27 32 37

26 31 36 41

26 31 36 41

140-159

18 19 20 21

23 24 25 26

21 25 29 34

24 28 33 38

24 28 33 38

120-139

16 17 18 19

20 21 22 23

19 22 26 31

22 25 30 34

22 25 30 34

100-119

15 15 16 17

18 19 20 21

17 20 24 28

19 23 27 31

19 23 27 31

160-179

15 15 16 17

21 22 23 24

19 21 24 27

24 27 31 34

24 27 31 34

140-159

13 13 14 15

18 19 20 21

16 18 21 23

21 23 26 30

21 23 26 30

120-139

11 11 12 13

15 16 17 18

14 15 18 20

18 20 23 26

18 20 23 26

100-119

9 10 10 11

13 14 15 15

12 13 15 17

15 17 19 22

15 17 19 22

160-179

10 11 12 12

17 18 19 20

15 16 18 19

22 24 26 28

22 24 26 28

140-159

9 9 10 10

14 15 16 16

12 13 14 16

18 19 21 23

18 19 21 23

120-139

7 7 8 8

11 12 13 14

10 11 12 13

14 16 17 19

14 16 17 19

100-119

6 6 6 7

9 10 10 11

8 8 9 10

12 13 14 15

12 13 14 15

SCORE2 and SCORE2-OP risk chart for fatal and non-fatal (MI, stroke) ASCVD

Low CVD Risk (1)

SCORE2

160-179

8 8 9 9 12 12 13 13

65-69

11 12 12 13 15 16 17 19

140-159

7 7 7 7 10 10 11 11

9 10 11 11 13 14 15 16

120-139

5 6 6 6 8 9 9 9

8 8 9 10 11 12 13 13

100-119

5 5 5 5 7 7 7 8

6 7 7 8 9 10 11 11

160-179

6 6 7 7 10 10 11 11

8 9 10 11 13 14 15 17

140-159

5 5 5 6 8 8 9 9

7 8 8 9 10 11 13 14

120-139

4 4 4 5 6 7 7 8

6 6 7 8 9 10 10 11

100-119

3 3 4 4 5 6 6 6

5 5 6 6 7 8 9 10

160-179

4 5 5 5 8 8 9 10

7 7 8 9 10 12 13 15

140-159

3 4 4 4 6 7 7 8

5 6 7 8 9 10 11 12

120-139

3 3 3 3 5 6 6 6

4 5 5 6 7 8 9 10

100-119

2 2 3 3 4 4 5 5

4 4 4 5 6 6 7 8

160-179

3 4 4 4 6 7 7 8

5 6 7 8 9 10 11 13

140-159

3 3 3 3 5 5 6 6

4 5 5 6 7 8 9 10

120-139

2 2 2 3 4 4 5 5

3 4 4 5 6 6 7 8

100-119

2 2 2 2 3 3 4 4

3 3 3 4 4 5 6 7

160-179

2 3 3 3 5 5 6 7

4 5 6 6 7 8 10 11

140-159

2 2 2 3 4 4 5 5

3 4 4 5 6 7 8 9

120-139

1 2 2 2 3 3 4 4

2 3 3 4 4 5 6 7

100-119

1 1 1 1 2 2 3 3

2 2 3 3 3 4 5 5

160-179

2 2 2 3 4 4 5 6

3 4 5 5 6 7 8 10

140-159

1 2 2 2 3 3 4 4

2 3 3 4 5 5 6 8

120-139

1 1 1 1 2 3 3 3

2 2 3 3 3 4 5 6


100-119

1 1 1 1 2 2 2 2

1 2 2 2 3 3 4 5

SCORE2 and SCORE2-OP risk chart for fatal and non-fatal (MI, stroke) ASCVD

Low CVD Risk (2)



Schematic representation of increasing 10-year CVD risk thresholds across age groups

CVD risk categories based on SCORE2 and SCORE2-OP in apparently healthy people according to age

	<50 years	50-69 years	≥70 years ^a
Low-to-moderate CVD risk: risk factor treatment generally not recommended	<2.5%	<5%	<7.5%
High CVD risk: risk factor treatment should be considered	2.5 to <7.5%	5 to <10%	7.5 to <15%
Very high CVD risk: risk factor treatment generally recommended ^a	≥7.5%	≥10%	≥15%

- The cut-off risk levels for risk categories are numerically different for various age groups to **avoid undertreatment in the young** and to **avoid overtreatment in older persons**.
- As age is a major driver of CVD risk, but **lifelong risk factor treatment benefit is higher in younger people**, the risk thresholds for considering treatment are lower for younger people

Recommendation for CVD risk communication



Recommendation	Class ^a	Level ^b
An informed discussion about CVD risk and treatment benefits tailored to the needs of a patient is recommended. ⁹⁶	I	C


- Reducing CVD risk at the individual level begins with **appropriate assessment of individual risk** and **effective communication** of risk and anticipated risk reduction by risk factor treatment.
- **Risk perception:** It is important to ensure that patients understand their risk, the anticipated risk reduction, and the pros and cons of intervention, and to identify what is important to them.

Treatment of risk factors in primary prevention


Recommendations	Class
Treatment of ASCVD risk factors <u>is recommended</u> in apparently healthy people without DM, CKD, genetic/rarer lipid or BP disorders who are at very high CVD risk (SCORE2 $\geq 7.5\%$ for age under 50; SCORE2 $\geq 10\%$ for age 50–69; SCORE2-OP $\geq 15\%$ for age ≥ 70).	I
Treatment of ASCVD risk factors <u>should be considered</u> in apparently healthy people without DM, CKD, genetic/rarer lipid, or BP disorders who are at high CVD risk (SCORE2 2.5 to $< 7.5\%$ for age under 50; SCORE2 5 to $< 10\%$ for age 50–69; SCORE2-OP 7.5 to $< 15\%$ for age ≥ 70 years), taking ASCVD risk modifiers, lifetime risk and treatment benefit, and patient preferences into account.	IIa

Treatment of risk factors in relation to total CVD risk

- The **intensity of treatment** should increase with increasing CVD risk.
- **No lower threshold** of total CVD risk precludes treatment of risk factors.
- Conversely, **no high threshold** for total CVD risk implies 'mandatory' treatment




Stepwise approach to risk stratification and treatment options



Cardiovascular risk and risk factor treatment in patients with **established CVD**

ESC Prevention guidelines: Opportunities and Challenges



Opportunities


- More robust and better validated **tools for risk assessment**, including individuals who were previously not addressed (e.g. elderly)
- **Physician – patient communication** becomes central in defining the preventive strategy for each patient
- **Shared decision-making** - No paternalistic approach
- No "**one size fits all**" concept: There is no single "correct " approach; rather, the individual's preferences and understanding are taken into account.
- Important steps towards **individualized management**

Challenges

- Further steps needed to move from crude risk assessment to in-depth phenotyping and **refined risk stratification**
- Beyond classical risk factors, integration of potential **risk modifiers** in risk assessment tools remains challenging
- Integration of the **voice of the patient** in every-day clinical practice
- Geographic and socioeconomic **disparities and inequalities**: profound differences in access to risk assessment and risk reduction strategies even within ESC member countries


Challenges

Despite major advances in risk assessment and management, the **achievement of recommended treatment targets remains suboptimal**



Challenges

Despite major advances in risk assessment and management, the **achievement of recommended treatment targets remains suboptimal**



Proportion of patients with LDL-C >70 mg/dL after an MI / ACS event


1. Reiner Z, et al. *Atherosclerosis* 2016;246:243-50

2. De Backer G, et al. *Atherosclerosis* 2019;285:135-46.

3. Koskinas KC, et al. *Eur J Preventive Cardiology* 2021;28(1):59-65

Challenges

Addressing Multiple Aspects of Residual CV Risk





 **INSELSPITAL**
*UNIVERSITÄTSSPITAL BERN
HOPITAL UNIVERSITAIRE DE BERNE
BERN UNIVERSITY HOSPITAL*

Thank you very much for your attention

konstantinos.koskinas@insel.ch